|
See related Lyrinel XR tab information |
|
|
|
Manufacturer |
Janssen-Cilag |
|
Distributor |
DKSH |
|
Contents |
Oxybutynin Cl |
|
Indications |
Treatment of overactive bladder w/ symptoms of urinary incontinence, urgency & frequency in adults. Treatment of childn ≥6 yr w/ symptoms of detrusor overactivity associated w/ a neurological condition (eg spina bifida). |
|
Dosage |
Adult & elderly ≥65 yr 5-10 mg once daily; may be adjusted by 5 mg/day (max: 30 mg/day) in intervals of at least 1 wk. Childn ≥6 yr 5 mg once daily; max: 20 mg/day. |
|
Administration |
May be taken with or without food (Swallow whole, do not chew/divide/crush.). |
|
Contraindications |
Urinary retention, gastric retention & other severe decreased GI motility conditions, uncontrolled narrow-angle glaucoma. |
|
Special Precautions |
Monitor for anticholinergic CNS effects. Hepatic or renal impairment, bladder outflow obstruction, GI obstructive & GI motility disorders, ulcerative colitis, myasthenia gravis, gastroesophageal reflux; preexisting severe GI narrowing & dementia. May impair ability to drive or operate machinery. Pregnancy & lactation. |
|
Adverse Drug Reactions |
UTI, headache, somnolence, dizziness, keratoconjunctivitis sicca, blurred vision, dry mouth, constipation, diarrhea, nausea, dyspepsia, urinary retention, heat prostration.
View ADR Monitoring Form |
|
Drug Interactions |
Other anticholinergics, digitalis, ketoconazole, antimycotic agents (itraconazole, miconazole) or macrolides (erythromycin, clarithromycin).
View more drug interactions with Lyrinel |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
